Rep. Rick Larsen Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Posted by Tammy Falkenburg on Jul 18th, 2026

Representative Rick Larsen (Democratic-Washington) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on July 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on July 8th. The trade occurred in the Representative’s “RICHARD R LARSEN IRA” account.

Representative Rick Larsen also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Amphenol (NYSE:APH) on 7/8/2026.
Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 7/8/2026.
Sold $1,001 – $15,000 in shares of S&P Global (NYSE:SPGI) on 7/8/2026.

Abbott Laboratories Trading Up 1.9%

NYSE:ABT traded up $1.88 during trading hours on Friday, hitting $100.71. The company had a trading volume of 19,913,032 shares, compared to its average volume of 11,962,257. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a market cap of $175.41 billion, a P/E ratio of 32.59, a P/E/G ratio of 1.70 and a beta of 0.61. The company has a 50-day moving average of $89.89 and a 200 day moving average of $102.17. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. The company’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. BTIG Research upped their price target on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. Evercore decreased their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Argus dropped their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, Barclays cut their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $118.61.

Read Our Latest Research Report on ABT

Institutional Trading of Abbott Laboratories

Several hedge funds have recently modified their holdings of the business. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories during the fourth quarter worth about $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

About Representative Larsen

Rick Larsen (Democratic Party) is a member of the U.S. House, representing Washington’s 2nd Congressional District. He assumed office on January 3, 2001. His current term ends on January 3, 2027.

Larsen (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 2nd Congressional District. He declared candidacy for the 2026 election.

Since at least 2011, Larsen has been assigned to the Committee on Armed Services and the Committee on Transportation and Infrastructure.

Larsen’s first position as an elected official was in 1998 as a member of the Snohomish County Council.

Larsen earned his bachelor’s degree from Pacific Lutheran University. After earning his master’s degree in public affairs from the University of Minnesota, Larsen worked as the director of public affairs for the Washington State Dental Association and then as an economic development official with the Port of Everett. He went on to serve on the Snohomish County Council before seeking election to the U.S. House.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.